Movement Alert|Kodiak Sciences Inc. Falls 4.09% in Regular Trading, Market Continues to Digest Wider Q3 Loss and Expense Pressure

Market Focus11-16

On November 16, Kodiak Sciences Inc. fell 4.09% in Regular Trading, trading at $103.14 per share, with turnover of $22.8831 million.

The move appears tied to continued market digestion of the company’s latest quarterly results, which showed a wider third-quarter loss, higher research and development spending, and ongoing cash-consumption concerns.

Kodiak Sciences Inc. reported third-quarter EPS of $(1.05), missing the $(1.01) consensus estimate, while net loss widened 8% year over year to $66.22 million. Research and development expense rose 16% to $58.30 million, driven mainly by increased clinical and manufacturing activity. Although the company said multi-indication regulatory submissions for Zenkuda remain planned for the fourth quarter and at least one firm raised its price target to $150, near-term trading focus has stayed on the earnings miss and cost pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment